Company profile: Avacta
1.1 - Company Overview
Company description
- Provider of technologies, consumables and reagents for life science markets from drug discovery to diagnostics; engaged in research, development, production and delivery of instrumentation and services for biopharmaceutical drug development and clinical diagnostics using biophysical technology. Offerings include the pre|CISION Platform, Affimer Technology, AVA6000, Launch Diagnostics (UK/France), and Coris Bioconcept rapid diagnostic test kits.
Products and services
- Affimer® Technology: Biologic platform offering alternatives to antibodies for developing immunotherapies and improving immunodiagnostics in life science markets
- Pre|CISION™ Platform: Protease-activated, tumour-specific drug delivery system concentrating potent drugs in the tumour microenvironment while minimizing exposure to healthy tissues in biopharmaceutical development
- AVA6000: Peptide drug conjugate form of doxorubicin targeting tumour-specific fibroblast activation protein to release the drug within tumour tissues for precise localization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avacta
Aulos Bioscience
HQ: United States
Website
- Description: Provider of cancer immuno-oncology therapeutics, including AU-007, a computationally designed human IgG1 monoclonal antibody that selectively binds to the CD25-binding portion of IL-2 to prevent immune suppression, reduce toxic side effects, and enhance immune activation against solid tumors; plus an AI discovery platform by Biolojic Design using machine learning algorithms to design specific, highly selective functional monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aulos Bioscience company profile →
Arc Medical
HQ: United Kingdom
Website
- Description: Provider of award-winning, innovative medical products designed to increase Adenoma Detection Rates (ADR) and improve retrieval methods, focusing on enhancing physician experience and patient outcomes with cost effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arc Medical company profile →
ArcherDX
HQ: United States
Website
- Description: Provider of NGS-based assay solutions advancing molecular pathology, using proprietary Anchored Multiplex PCR (AMP) chemistry and Archer Analysis software to detect genetic mutations for solid tumor, blood cancer, and genetic disease research. Offers VARIANTPlex DNA panels, FUSIONPlex RNA panels, LIQUIDPlex ctDNA panels, IMMUNOVerse immune profiling assays, and an Assay Marketplace for custom NGS panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArcherDX company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avacta
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avacta
2.2 - Growth funds investing in similar companies to Avacta
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avacta
4.2 - Public trading comparable groups for Avacta
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →